Luye Pharma Group Ltd. (HKG:2186)
Hong Kong · Delayed Price · Currency is HKD 1.750
+0.050 (2.94%)
Sep 18, 2026, 4:08 PM HKT
Luye Pharma Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,129 | 6,308 | 6,061 | 6,143 | 5,982 | 5,200 | |
Revenue Growth | -0.63% | 4.07% | -1.33% | 2.70% | 15.03% | -6.13% |
Cost of Revenue | 2,222 | 2,146 | 2,017 | 1,939 | 1,841 | 1,803 |
Gross Profit | 3,907 | 4,163 | 4,044 | 4,204 | 4,141 | 3,397 |
Selling, General & Admin | 2,297 | 2,506 | 2,398 | 2,700 | 2,403 | 2,276 |
Other Operating Expenses | 443.68 | 439.15 | 509.26 | 616.6 | 948.82 | 757.72 |
Operating Expenses | 2,740 | 2,945 | 2,908 | 3,317 | 3,351 | 3,033 |
Operating Income | 1,167 | 1,218 | 1,137 | 887.44 | 789.14 | 363.4 |
Interest Expense | -652.42 | -686.6 | -561.79 | -675.45 | -471.76 | -399.46 |
Interest & Investment Income | 152.8 | 152.8 | 157.19 | 209.97 | 176.1 | 189.69 |
Earnings From Equity Investments | -35.7 | -31.57 | -0.77 | 0.79 | 0.83 | 0.7 |
Currency Exchange Gain (Loss) | -75.83 | 104.54 | -71.73 | 46.03 | 106.2 | -24.09 |
Other Non Operating Income (Expenses) | 315.98 | 57.15 | 182.5 | 241.77 | 109.08 | 129.65 |
EBT Excluding Unusual Items | 871.74 | 813.97 | 841.98 | 710.54 | 709.59 | 259.88 |
Gain (Loss) on Sale of Investments | 149.03 | 149.03 | 1.79 | 1.94 | 1.55 | -14.81 |
Gain (Loss) on Sale of Assets | -4.96 | -4.96 | 18.49 | 1.5 | -0.21 | 11.36 |
Legal Settlements | -14.58 | -14.58 | -14.65 | -14.52 | -14.07 | -273.48 |
Other Unusual Items | 1.17 | 1.17 | -8.39 | 0.63 | -27.09 | -57.51 |
Pretax Income | 1,002 | 944.64 | 839.22 | 700.1 | 669.76 | -74.56 |
Income Tax Expense | 273.33 | 238.98 | 194.21 | 161.02 | 86.47 | 70.23 |
Earnings From Continuing Operations | 729.08 | 705.66 | 645.01 | 539.08 | 583.3 | -144.78 |
Minority Interest in Earnings | -32.72 | -86.91 | -173.12 | -6.47 | 21.51 | 10.39 |
Net Income | 696.36 | 618.75 | 471.89 | 532.61 | 604.81 | -134.39 |
Net Income to Common | 696.36 | 618.75 | 471.89 | 532.61 | 604.81 | -134.39 |
Net Income Growth | 75.43% | 31.12% | -11.40% | -11.94% | - | - |
Shares Outstanding (Basic) | 4,012 | 3,896 | 3,762 | 3,728 | 3,481 | 3,445 |
Shares Outstanding (Diluted) | 4,012 | 3,896 | 3,762 | 3,728 | 3,481 | 3,445 |
Shares Change | 6.66% | 3.57% | 0.89% | 7.11% | 1.03% | 7.87% |
EPS (Basic) | 0.17 | 0.16 | 0.13 | 0.14 | 0.17 | -0.04 |
EPS (Diluted) | 0.17 | 0.16 | 0.13 | 0.14 | 0.17 | -0.04 |
EPS Growth | 64.49% | 26.65% | -12.22% | -17.78% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 1,272 | -426.31 | 962.83 | 998.11 | -373.83 |
Free Cash Flow Per Share | - | 0.33 | -0.11 | 0.26 | 0.29 | -0.11 |
Gross Margin | 63.75% | 65.98% | 66.72% | 68.44% | 69.22% | 65.32% |
Operating Margin | 19.04% | 19.30% | 18.75% | 14.45% | 13.19% | 6.99% |
Profit Margin | 11.36% | 9.81% | 7.79% | 8.67% | 10.11% | -2.58% |
Free Cash Flow Margin | - | 20.16% | -7.03% | 15.67% | 16.69% | -7.19% |
EBITDA | 1,969 | 2,014 | 1,892 | 1,553 | 1,426 | 906.88 |
EBITDA Margin | 32.12% | 31.93% | 31.21% | 25.28% | 23.83% | 17.44% |
D&A For EBITDA | 801.86 | 796.74 | 755 | 665.47 | 636.47 | 543.48 |
EBIT | 1,167 | 1,218 | 1,137 | 887.44 | 789.14 | 363.4 |
EBIT Margin | 19.04% | 19.30% | 18.75% | 14.45% | 13.19% | 6.99% |
Effective Tax Rate | 27.27% | 25.30% | 23.14% | 23.00% | 12.91% | - |